Scholarlink

Objective <p>Tyrosinemia is a rare autosomal recessive inborn error of metabolism caused by a deficiency of fumarylacetoacetate hydrolase (FAH). This leads to the accumulation of toxic metabolites, resulting in progressive liver and kidney damage. This study aimed to evaluate the serum levels of the long non-coding RNAs NEAT1 and MALAT1 in children with tyrosinemia and assess their potential as diagnostic biomarkers.</p> Methods <p>This cross-sectional study included 11 children with tyrosinemia, randomly selected from the Shiraz Pediatric Liver Cirrhosis Cohort Study (SPLCCS), and 26 healthy controls. RNA was extracted from serum samples, and the expression levels of NEAT1 and MALAT1 were quantified using quantitative real-time PCR.</p> Results <p>Serum NEAT1 expression was significantly upregulated in children with tyrosinemia compared to healthy controls (<i>p</i> = 0.011). In contrast, MALAT1 expression showed a non-significant increasing trend. Correlation analysis revealed a positive association between NEAT1 expression and AST and ALP levels, whereas MALAT1 was inversely correlated with INR in the tyrosinemia group. Receiver operating characteristic (ROC) curve analysis demonstrated that NEAT1 has strong diagnostic potential, with an area under the curve (AUC) of 0.945, 100% sensitivity, and 80% specificity at an optimal cut-off value of 1.126. MALAT1 showed poor diagnostic performance.</p> Conclusions <p>Our findings suggest that serum NEAT1 represents a promising, non-invasive biomarker for tyrosinemia. In contrast, MALAT1 does not appear to be a useful diagnostic marker for this condition.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of serum NEAT1 and MALAT1 expression as diagnostic biomarkers in tyrosinemia, a rare metabolic disorder

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Nasrin Motazedian,
  • Mohsen Mohammadi,
  • Negar Azarpira,
  • Kimia Falamarzi,
  • Bita Geramizadeh,
  • Seyed Mohsen Dehghani,
  • Mahdokht Hossein-Aghdaie,
  • Seyed Ali Malekhosseini,
  • Mahintaj Dara

摘要

Objective

Tyrosinemia is a rare autosomal recessive inborn error of metabolism caused by a deficiency of fumarylacetoacetate hydrolase (FAH). This leads to the accumulation of toxic metabolites, resulting in progressive liver and kidney damage. This study aimed to evaluate the serum levels of the long non-coding RNAs NEAT1 and MALAT1 in children with tyrosinemia and assess their potential as diagnostic biomarkers.

Methods

This cross-sectional study included 11 children with tyrosinemia, randomly selected from the Shiraz Pediatric Liver Cirrhosis Cohort Study (SPLCCS), and 26 healthy controls. RNA was extracted from serum samples, and the expression levels of NEAT1 and MALAT1 were quantified using quantitative real-time PCR.

Results

Serum NEAT1 expression was significantly upregulated in children with tyrosinemia compared to healthy controls (p = 0.011). In contrast, MALAT1 expression showed a non-significant increasing trend. Correlation analysis revealed a positive association between NEAT1 expression and AST and ALP levels, whereas MALAT1 was inversely correlated with INR in the tyrosinemia group. Receiver operating characteristic (ROC) curve analysis demonstrated that NEAT1 has strong diagnostic potential, with an area under the curve (AUC) of 0.945, 100% sensitivity, and 80% specificity at an optimal cut-off value of 1.126. MALAT1 showed poor diagnostic performance.

Conclusions

Our findings suggest that serum NEAT1 represents a promising, non-invasive biomarker for tyrosinemia. In contrast, MALAT1 does not appear to be a useful diagnostic marker for this condition.

Clinical trial number

Not applicable.